Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside

Table 2 The five main HIPEC schemes used in the clinical practice with the corresponding cytotoxic drugs adopted. Clinically relevant concentrations, dilutions, perfusion time and hyperthermia conditions were obtained from recorded perfusion data from the Peritoneal Malignancy Unit of Fondazione IRCCS Istituto dei Tumori di Milano. The mechanism of action of each cytotoxic drugs, the synergistic effect with heat and penetration index are also reported

HIPEC schemes
Scheme	Drug/s	Mechanism of action	Clinically relevant dose	Synergistic with heat	Penetration index (mm)	Perfusion time (min)	T (C°)
#1	Mitomycin-C	Antitumor antibiotic (methylazirinopyrroloindoledione antineoplastic)	35 mg/m²	Yes	2	60	42.5
#2	Mitomycin-C + Cisplatin	Mitomycin-C: Antitumor antibiotic (methylazirinopyrroloindoledione antineoplastic) Cisplatin: Alkylating agent	Mitomicyn-C: 3.5 mg/m² Cisplatin: 25 mg/m²	Yes	Mitomycin-C: 2 Cisplatin: 1–3	60	42.5
#3	Doxorubicin + Cisplatin	Doxorubicin: Antitumor antibiotic (anthracycline topoisomerase inhibitor) Cisplatin: Alkylating agent	Doxorubicin: 15 mg/L Cisplatin: 43 mg/L	Yes	Doxorubicin: 4–6 cell layers Cisplatin: 1–3	90	42.5
#4	Oxaliplatin_low-dose	Alkylating agent	200 mg/m²	Yes	1–2	120	42.5
#5	Oxaliplatin_high-dose	Alkylating agent	460 mg/m²	Yes	1–2	30	42.5

ISSN: 1756-9966